BridgeBio Pharma Inc to Discuss Phase 2b Data and Phase 3 Trial Design for Encaleret in ADH1- Conference Call Transcript
Thank you for standing by, and welcome to the BridgeBio Pharma to discuss Phase IIb data and Phase III trial design for Encaleret in ADH1. (Operator Instructions) As a reminder, this conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Dr. Neil Kumar, Chief Executive Officer of BridgeBio. The floor is yours.
Thanks so much, operator, and thanks to everyone joining us for your time. Before I dive in, I just wanted to remind everyone that I will be making forward-looking statements today. And if you need additional details, please refer to our SEC filings.
It's my privilege to kick this call off and introduce our most recent data from our Phase II ADH1 or autosomal dominant hypocalcemia type 1 program. Drs. Rachel Gafni and Mary Scott Roberts will provide the bulk of what's going to be useful today on this call. But I wanted to take a moment to set up the discussion and provide a bit of perspective.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
